We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Infliximab for Refractory Ulcerative Colitis.
- Authors
Chey, William Y.; Hussain, Ayub; Ryan, Charlotte; Potter, Gregory D.; Shah, Ashok
- Abstract
Eight patients with active ulcerative colitis (UC). refractory to usual combination medical therapy, were treated with a single i.v. dose of chimeric monoclonal antibody to recombinant human tumor necrosis factor α many of these patients were scheduled for surgical colectomy because of their active disease. All patients responded extremely well to a single 5 mg/kg infusion of infliximab. with marked improvement after the infusion clinically, colonoscopically, and histologically on colonic biopsy. There were no significant complications or side effects: mean duration of remission has not been determined because none of the patients have relapsed. Infliximab appears to be a potent agent for inducing remission in refractory patients with ulcerative colitis.
- Subjects
ULCERATIVE colitis; INFLIXIMAB; MONOCLONAL antibodies; RECOMBINANT antibodies; TUMOR necrosis factors; COLECTOMY
- Publication
American Journal of Gastroenterology (Springer Nature), 2001, Vol 96, Issue 8, p2373
- ISSN
0002-9270
- Publication type
Article
- DOI
10.1111/j.1572-0241.2001.04039.x